Chitosan modified 5-fluorouracil nanostructured lipid carriers for treatment of diabetic retinopathy in rats: a new dimension to an anticancer drug

Simple item page
dc.catalogadorpva
dc.contributor.authorSharma, D.S.
dc.contributor.authorWadhwa, S.
dc.contributor.authorGulati, M.
dc.contributor.authorKumar, B.
dc.contributor.authorVishwas, S.
dc.contributor.authorKhursheed, R.
dc.contributor.authorSaini, S.
dc.contributor.authorKumar, A.
dc.contributor.authorParveen, S.R.
dc.contributor.authorSingh, S.K.
dc.contributor.authorDua, K.
dc.contributor.authorChitranshi, N.
dc.contributor.authorGupta, V.K.
dc.contributor.authorAlrouji, M.
dc.contributor.authorAlhajlah, S.
dc.contributor.authorAlOmeir, O.
dc.contributor.authorGupta, G.
dc.contributor.authorZacconi, Flavia C. M.
dc.contributor.authorChellappan, D.K.
dc.contributor.authorMorris, A.
dc.contributor.authorLoebenberg, R.
dc.date.accessioned2023-08-22T16:40:19Z
dc.date.available2023-08-22T16:40:19Z
dc.date.issued2022
dc.description.abstractDiabetic retinopathy (DR) is one of the chronic complications of diabetes. It includes retinal blood vessels' damage. If untreated, it leads to loss of vision. The existing treatment strategies for DR are expensive, invasive, and need expertise during administration. Hence, there is a need to develop a non-invasive topical formulation that can penetrate deep to the posterior segment of retina and treat the damaged retinal vessels. In addition, it should also provide sustained release. In recent years, novel drug delivery systems (NDDS) have been explored for treating DR and found successful. In this study, chitosan (CS) modified 5-Fluorouracil Nanostructured Lipid Carriers (CS-5-FU-NLCs) were prepared by modified melt emulsification-ultrasonication method and optimized by Box-Behnken Design. The size, polydispersity index, zeta potential and entrapment efficiency of CS-5-FU-NLCs were 163.2 ± 2.3 nm, 0.28 ± 1.52, 21.4 ± 0.5 mV and 85.0 ± 0.2 %, respectively. The in vitro drug release and ex vivo permeation study confirmed higher and sustained drug release in CS-5-FU-NLCs as compared to 5-FU solution. HET-CAM Model ensured the non-irritant nature of CS-5-FU-NLCs. In vivo ocular studies of CS-5-FU-NLCs confirmed antiangiogenic effect of 5-FU by CAM model and diabetic retinopathy induced rat model, indicating successful delivery of 5-FU to the retina.
dc.fechaingreso.objetodigital2023-08-22
dc.fuente.origenSCOPUS
dc.identifier.doi10.1016/j.ijbiomac.2022.10.168
dc.identifier.eissn1879-90003
dc.identifier.issn0141-8130
dc.identifier.pubmedid36302483
dc.identifier.scopusidSCOPUS_ID:85140997274
dc.identifier.urihttps://doi.org/10.1016/j.ijbiomac.2022.10.168
dc.identifier.uriwww.elsevier.com/locate/ijbiomac
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/74447
dc.information.autorucInstituto de Ingeniería Biológica y Médica; Zacconi, Flavia C. M.;0000-0002-3676-0453; 1011127
dc.language.isoen
dc.nota.accesoContenido parcial
dc.pagina.final830
dc.pagina.inicio810
dc.publisherElsevier B.V.
dc.relation.ispartofInternational Journal of Biological Macromolecules
dc.revistaInternational Journal of Biological Macromoleculeses_ES
dc.rightsacceso restringido
dc.subject5-Fluorouraciles_ES
dc.subjectChitosanes_ES
dc.subjectNanostructured lipid carrierses_ES
dc.subject.ddc570
dc.subject.deweyBiologíaes_ES
dc.subject.ods03 Good health and well-being
dc.subject.odspa03 Salud y bienestar
dc.titleChitosan modified 5-fluorouracil nanostructured lipid carriers for treatment of diabetic retinopathy in rats: a new dimension to an anticancer druges_ES
dc.typeartículo
dc.volumen224
sipa.indexSCOPUS
sipa.trazabilidadSCOPUS;10-11-2022
sipa.trazabilidadORCID;2023-08-21
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Chitosan modified 5-fluorouracil.pdf
Size:
11.53 KB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Artículos de revistas